

**CERTIFICATE OF A PHARMACEUTICAL PRODUCT<sup>1</sup>**

No of Certificate : 3566999/TS/2022

Valid UpTo: **25/06/2025**

1.Name and Dosage form of Product:

Exporting(Certifying)Country: **INDIA**

**Selexipag Tablets 1400mcg Each film coated Tablet contains Selexipag 1400 mcg**

1.1 Active Ingredients(s)<sup>2</sup> and amount(s) per unit dose<sup>3</sup>:

Importing(Requesting) country **Chile**

Active ingredients (s): Selexipag 1H 1.400 mgFor complete composition including excipients, see attachedLactose Monohydrate (Lactochem fine powder) USP-NF 50.900 mg, Microcrystalline Cellulose (Avicel PH 101) USP-NF 47.500 mg, Hydroxy propyl cellulose (Klucel- LF Pharm) USP-NF 5.400 mg, Granulated corn starch (Grastar) USP-NF 21.000 mg, Low substituted hydroxy propyl cellulose (L-HPC-LH 11) USP-NF 6.800 mg, Magnesium Stearate (LIGAMED MF-2-V) USP-NF 2.000 mg, Opadry Yellow 03H520052 1H 5.000 mg, Purified Water USP Q.S

For complete qualitative composition including excipients see above<sup>4</sup>

1.2 Is this Product licensed to be placed on the market for use in Exporting country?<sup>5</sup>

**Yes**

1.3 Is this product actually on the marketing in the Exporting Country?

**Yes**

If the answer to 1.2 is Yes, continue with section 2A and omit section 2B.If the answer to 1.2 is No, omit section 2A continue with section 2B<sup>6</sup>

2A.1 Number of Product Licence<sup>7</sup>: **L.Dis.No.2186906/TS/2022, 5/MN/TS/2014/F/G, S.NO:13 , Dated: 31/12/2021**

2B.1 Applicant for Certificate(Name and Address)

2B.2 Status of Applicant<sup>8</sup>

2A.2 Product License Holder(Name and address): M/s MSN LABORATORIES PRIVATE LIMITED, Formulation Division, Unit-II, Sy. No.1277 & 1319 to 1324, Nandigama (Village & Mandal), Rangareddy District - 509228, Telangana State, India.

2A.3 Status of License Holders<sup>8</sup> : a

2A.3.1 For Category b and c the name and address of the manufacturer producing the dosage form is <sup>9</sup> na

2A.4 Is Summary basis of approval appended ? <sup>10</sup> No

2A.5 Is the Attached, officially approved production information complete and consonant with the license?<sup>11</sup>: Not Provided

2A.6 Applicant for Certificate, if different from licence holder (name and address) na

3 Does the certifying authority arrange for periodic section of the manufacturing plant in which the dosage form is produced?<sup>14</sup>

3.1 Periodicity of routine inspection(years)

**Once in a Year**

3.2 Has the Manufacture of this type of dosage from been inspected?

**Yes**

3.3 Do the facilities and operations conform to GMP as recommended by World Health Organization?<sup>15</sup>

**Yes**

4.0 Does the information Submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product?<sup>16</sup>

**Yes**

24-11-2022

**ATTESTED**  
**M. SADA SIVA KUMAR REDDY, B.Com., B.L.,**  
**ADVOCATE & NOTARY**  
Appointed by Govt., India  
G.O.Ms.No.198, Rev (Regn-II), dt. 11.04.2000  
102, Saraswathi Enclave, Bhayanagar Colony.





**DRUGS CONTROL ADMINISTRATION**  
**Government of Telangana**



Address of Certifying Authority.

Drugs Control Administration, Vengalraonagar, Hyderabad 500038, India

Telephone No : 91-040-23814119 Fax No : 91-040-23814360

Name of the authorized person:

Digitally Signed By

**RAMDHAN GUGULOTH**


**Deputy Director and Certifying Authority**

**DRUGS CONTROL ADMINISTRATION**

**TELANGANA STATE**


Date:24-11-2022 16:02:23 PM

This certificate conforms to the format recommended by the World Health Organization  
(General instructions and explanatory notes overleaf)




**Explanatory notes**

1. This certificate, which is in the format recommended by WHO, establishes the status of the pharmaceutical product and of the applicant for the certificate in the exporting country. It is for a single product only since manufacturing arrangements and approved information for different dosage forms and different strengths can vary.
2. Use whenever possible, International Non-proprietary Names (INNs) or national non-proprietary names.
3. The formula (complete composition) of dosage form should be given on the certificate or be appended.
4. Details of quantitative composition are preferred, but their provision is subject to the agreement of the product licence holder.
5. When applicable, append details of any restriction applied to the sale, distribution or administration of the product that is specified in the product licence.
6. Sections 2A and 2B are mutually exclusive.
7. Indicate when applicable, if the license is provisional, or the product has not yet been approved.
8. Specify whether the person responsible for placing the product on the market:
  - (a) manufactures the dosage form;
  - (b) packages and/or labels a dosage form manufactured by an independent company; or
  - (c) is involved in none of the above
9. This information can be provided only with the consent of the product license holder or, in the case of non registered products, the applicant. Non-completion of this section indicates that the party concerned has not agreed to inclusion of this information. It should be noted that information concerning the site of production is part of the product license. If the production site is changed, the license must be updated or it will cease to be valid.
10. This refers to the document, prepared by some national regulatory authorities, that summarizes the technical basis on which the product has been licensed.
11. This refers to the product information approved by the competent national regulatory authority, such as a Summary of Product Characteristics (SmPC).
12. In this circumstance, permission for issuing the certificate is required from the product license holder. This permission must be provided to the authority by the applicant.
13. Please indicate the reason that the applicant has provided for not requesting registration:
  - (a) the product has been developed exclusively for the treatment of conditions – particularly tropical diseases – not endemic in the country of export;
  - (b) the product has been reformulated with a view to improving its stability under tropical conditions;
  - (c) the product has been reformulated to exclude excipients not approved for use in pharmaceutical products in the country of import;
  - (d) the product has been reformulated to meet a different maximum dosage limit for an active ingredient;
  - (e) any reason, please specify.
14. Not applicable means that the manufacture is taking place in a country other than that issuing the product certificate and inspection is conducted under the aegis of the country of manufacture.
15. The requirements for good practices in the manufacture and quality control of drugs referred to in the certificate are those included in the thirty-second report of the Expert Committee on Specifications for Pharmaceutical Preparations (WHO Technical Report Series No. 823, 1992 Annex 1). Recommendations specifically applicable to biological products have been formulated by the WHO Expert Committee on Biological Standardization (WHO Technical Report Series, No. 822, 1992 Annex 1)
16. This section is to be completed when the product license holder or applicant conforms to status (b) or (c) as described in note 8 above. It is of Particular importance when foreign contractors are involved in the manufacture of the product. In these circumstances the applicant should supply the certifying authority with information to identify the contracting parties responsible for each stage of manufacture of the finished dosage form, and the extent and nature of any controls exercised over each of these parties.







CP  
MSN

9C

12

भारत सरकार / GOVERNMENT OF INDIA  
अपोस्टिल / APOSTILLE  
(Convention de La Haye du 5 octobre 1961)

Country: REPUBLIC OF INDIA

**This public document**  
COMMERCIAL DOCUMENT  
has been signed by: RAMDHAN GUGULOTH  
acting in the capacity of: DY. DIRECTOR  
bears the seal/stamp of: INDO LATIN AMERICAN CHAMBER OF  
COMMERCE, NEW DELHI

**Certified**  
at: NEW DELHI, INDIA the 17-Apr-2023  
by: SO (OI/Attestation) MINISTRY OF EXTERNAL AFFAIRS  
No: DLND0001657623

Seal / Stamp: [Stamp]

is issued to: MEN LABORATORIES PVT. LTD.

Signature: [Signature]

01 1001353

The Ministry of External Affairs  
has the responsibility for the  
issuance of the Apostille documents



(नवल प्रभाकर थपलियाल)  
(Naval Prabhakar Thapliyal)  
अनुभाग अधिकारी (सात्यापन / ओ.आई.)  
Section Officer (Attestation/O.I.)  
सी.पी.डी. बंगला / C.P.V. Division  
विदेश मंत्रालय, नई दिल्ली  
Ministry of External Affairs, New Delhi